Ocular Therapeutix logo

Ocular Therapeutix

OCUL | NASDAQ
Chart Builder DCF Calculator
$6.01
-$0.20 (-3.22%)
At close: Nov 16, 2026, 4:00 PM ET
$6.00
-$0.01 (-0.17%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.22%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
30.7
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #771/1021 (Top 76%)

Key Statistics

Market Data

Market Cap $1.32B
1D Range
5.94 6.25
52W Range
5.94 16.11

Valuation (TTM)

PE -4.12
PB 3.00
EV/EBITDA -2.82

Valuation (NTM)

Forward PE N/A
Forward PEG -0.45
Price Target $25.00
Loading financial charts...

Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bio...

Sector Healthcare
Industry Biotechnology
Employees 325
IPO Date Jul 25, 2014
Fiscal Year January - December

Latest News

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript

8 days ago · seekingalpha.com

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call

8 days ago · marketbeat.com

What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

8 days ago · zacks.com

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

15 days ago · globenewswire.com

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

19 days ago · globenewswire.com

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

23 days ago · seekingalpha.com

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

24 days ago · seekingalpha.com

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

2 months ago · globenewswire.com

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

3 months ago · globenewswire.com

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

3 months ago · seekingalpha.com

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

Earnings

Latest Earnings
Nov 9, 2026
EPS
-$0.42
Miss -15.55%
REV
$12.87M
Miss -9.80%
Next Earnings
Feb 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$25.00
Upside
+315.97%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.